• Skip to primary navigation
  • Skip to main content
  • Skip to footer
MotherToBaby

MotherToBaby

Medications and More during pregnancy and breastfeeding

Search

Hide Search
Shopping Cart
Show SearchSearch
866.626.6847
  • About
    • Our Work
    • Our Team
    • About OTIS
    • In Your Area
    • Our Partners
    • Our Impact
  • Exposures
    • Pregnancy and Breastfeeding Exposures
    • Fact Sheets
    • Baby Blogs
    • Podcasts
    • Interactive Tool
    • Other Educational Tools
    • LactRx App
  • Studies
    • Ongoing Studies
    • What’s Involved?
    • Join Now
    • Refer a Patient
    • Health Providers
    • Pharma Industry
    • Publications
  • Health Professionals
    • Patient Education and Provider Resources
    • Refer a Patient
    • Request Materials
    • Annual Meeting
    • Exhibiting Schedule
    • FAQs
    • OTIS Membership
  • Media
    • Media Requests
    • Press Releases
    • eNews Sign Up
  • Donate
  • Contact
  • Show SearchSearch

Mirtazapine (Remeron®)

April 1, 2023

Selected References:

  • Aichhorn, Wolfgang et al. 2014. Mirtazapine and breast-feeding. The American journal of psychiatry 161,12 (2004): 2325.
  • Biswas PN, et al. 2003. The pharmacovigilance of mirtazapine: results of a prescription event monitoring study on 13,554 patients in England. J Psychopharmacol 17:121-6.
  • Carvalho, André F et al. 2016. The Safety, Tolerability and Risks Associated with the Use of Newer Generation Antidepressant Drugs: A Critical Review of the Literature. Psychotherapy and psychosomatics 85,5 (2016): 270-88.
  • Djulus J, et al. 2006. Exposure to mirtazapine during pregnancy: a prospective, comparative study of birth outcomes. J Clin Psychiatry 67(8):1280-4.
  • Einarson A, et al. 2009. Incidence of major malformations in infants following antidepressant exposure in pregnancy: results of a large prospective cohort study. Can J Psychiatry 54(4): 242-246.
  • Grigoriadis S, et al. 2013. The effect of prenatal antidepressant exposure on neonatal adaptation: a systematic review and meta-analysis. J Clin Psychiatry. 74(4):e309-20.
  • Goracci, Arianna et al. 2015. Benefici e potenziali rischi dell’utilizzo di antidepressivi in gravidanza: una revisione della letteratura [Antidepressant use in pregnancy: a critical review of the risk and benefits]. Rivista di psichiatria 50,3 (2015): 118-26.
  • Guclu S, et al. 2005. Mirtazapine use in resistant hyperemesis gravidarum: report of three cases and review of the literature. Arch Gynecol Obstet 272(4):298-300
  • Kieviet N, et al. 2015. Risk factors for poor neonatal adaptation after exposure to antidepressants in utero. Acta Paediatr 104(4):384-91.
  • Kjaersgaard MI, et al. 2013. Prenatal antidepressant exposure and risk of spontaneous abortion – a population-based study. PLoS One 8(8):e72095.
  • Klier C, et al. 2007. Mirtazapine and breastfeeding: maternal and infant plasma levels. Am J Psychiatry 164:2: 348-349.
  • Kristensen JH, et al. 2007. Transfer of the antidepressant mirtazapine into breast milk. Br J Clin Pharmacol 63:322-7.
  • Lennestal R. 2007. Delivery outcome in relation to maternal use of some recently introduced antidepressants. J Clin Psychopharmacology 27(6):607-613.
  • Milosavljević, Jovana Z et al. 2022. The effects of selective serotonin reuptake inhibitors on male and female fertility: a brief literature review. International journal of psychiatry in clinical practice 26,1 (2022): 43-49.
  • Ostenfeld, Anne et al. 2022. Mirtazapine exposure in pregnancy and fetal safety: A nationwide cohort study. Acta psychiatrica Scandinavica 145,6 (2022): 557-567.
  • Saks BR. 2001. Mirtazapine: treatment of depression, anxiety, and hyperemesis gravidarum in the pregnant patient: A report of 7 cases. Arch Womens Ment Health 3(4):165-170.
  • Schwarzer V, et al. 2008. Treatment resistant hyperemesis gravidarum in a patient with type I diabetes mellitus: neonatal withdrawal symptoms after successful antiemetic therapy with mirtazapine. Arch Gynecol Obstet 277:67-69.
  • Smit M, et al. 2016. Mirtazapine in pregnancy and lactation: A systemic review. European Neuropsychopharmacology 26:126-135.
  • Smit M, et al. 2015 Mirtazapine in pregnancy and lactation: Data from a case series. J Clin Psychopharmacol 35:163-7.
  • Sokolover N, et al. 2008. Neonatal recurrent prolonged hypothermia associated with maternal mirtazapine treatment during pregnancy. Can J Clin Pharmacol 15(2):e188-190.
  • Sołek, Przemysław et al. 2021. Molecular Consequences of Depression Treatment: A Potential In Vitro Mechanism for Antidepressants-Induced Reprotoxic Side Effects. International journal of molecular sciences 22,21 11855. 1
  • Solek, P et al. 2021. Toxic effect of antidepressants on male reproductive system cells: evaluation of possible fertility reduction mechanism. Journal of physiology and pharmacology: an official journal of the Polish Physiological Society 72,3 (2021): 10.26402/jpp.2021.3.06.
  • Tonn P, et al. 2009. High mirtazapine plasma levels in infant after breastfeeding: case report and review of the literature. J Clin Psychopharmacol 29(2):191-192.
  • Winterfeld U, et al. 2015. Pregnancy outcome following maternal exposure to mirtazapine: a multicenter, prospective study. J Clin Psychopharmacol 35(3):25.

Footer

               

Hot Links

  • Home
  • Exposures
  • Fact Sheets
  • Baby Blogs
  • Podcasts
  • Pregnancy Studies
  • Join a Study Now
  • Healthcare Professionals
  • Refer a Patient
  • Request Materials
  • News
  • Donate
  • Ask An Expert

Current Studies

  • Ankylosing Spondylitis
  • Constipation
  • Coronavirus (COVID-19)
  • Eczema (Moderate-to-Severe)/Atopic Dermatitis
  • Hidradenitis Suppurativa
  • Lupus
  • Multiple Sclerosis
  • Non-Radiographic Axial Spondyloarthritis
  • Psoriasis
  • Psoriatic Arthritis

Contact

Exposure Information Service
866.626.6847

Pregnancy Studies
877.311.8972

Media Inquiries
619.368.3259
nchavez@mothertobaby.org

MotherToBaby, a service of the Organization of Teratology Information Specialists

Copyright © 2025 The Organization of Teratology Information Specialists

  • Accessibility
  • Privacy
  • Terms
  • Site Map
^

This website is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $6,000,000 with zero percentage financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, HRSA, HHS, or the U.S. Government.